<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351100</url>
  </required_header>
  <id_info>
    <org_study_id>IRB No. 469/62</org_study_id>
    <nct_id>NCT04351100</nct_id>
  </id_info>
  <brief_title>Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients</brief_title>
  <official_title>Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dry eyes is multi-factorial disease which inflammation play etiological role. Diacerein is
      drug which has anti-inflammatory effect by antagonist Interleukin-1, decrease Interleukin-1
      receptor, increase Interleukin-1 Receptor antagonist. This observational study enrolled
      participants who going to take diacerein for osteoarthritis, measure corneal staining score,
      Ocular surface disease index score, Tear Osmolarity, Tear break up time, Schirmer 1 test,
      Interleukin-1 Receptor antagonist, Interleukin-1 alpha, Interleukin-1 beta level in tear at
      the time of enrollment and after 2 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal staining score change from baseline at 2 months</measure>
    <time_frame>At the time of enrollment and 2 months</time_frame>
    <description>Stain Cornea with Fluorescine, count and score staining at the cornea according to National eye institute : score 0-15 (0=no staining)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular surface disease index score</measure>
    <time_frame>At the time of enrollment and 2 months</time_frame>
    <description>Ocular Surface Disease Index : 0-100 (0=no any symptom)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Osmolarity</measure>
    <time_frame>At the time of enrollment and 2 months</time_frame>
    <description>Use Tearlab to measure tear osmolarity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear break up time</measure>
    <time_frame>At the time of enrollment and 2 months</time_frame>
    <description>Stain Cornea with Fluorescine, wait until tear film break, record time that tear break</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer 1 test</measure>
    <time_frame>At the time of enrollment and 2 months</time_frame>
    <description>place Schirmer strip at the fornix without anesthesia, wait for 5 min, record tear distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-1 receptor antagonist, Interleukin-1 alpha, Interleukin-1 beta level in tear</measure>
    <time_frame>At the time of enrollment and 2 months</time_frame>
    <description>Extract tear from Schirmer strip and use Bioplex for cytokine measurement of Interleukin-1 receptor antagonist(picogram/ml), Interleukin-1 alpha(picogram/ml), Interleukin-1 beta(picogram/ml)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Ocular Surface Disease</condition>
  <condition>Osteoarthritis</condition>
  <condition>Diacerein</condition>
  <arm_group>
    <arm_group_label>Diacerein group</arm_group_label>
    <description>Osteoarthritis and dry eye patients treated with Diacerein</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diacerein</intervention_name>
    <description>Diacerein prescribing by orthopedist. Dry eye sign and symptom was asses before start diacerein and after 2 months.</description>
    <arm_group_label>Diacerein group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tears within Schirmer paper
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with osteoarthritis that prescribed Diacerein at out-patient clinic,
        Department of Orthopedic, King Chulalongkorn Memorial Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Osteoarthritis with

          2. Ocular surface index score ≥ 13 with

          3. Corneal staining score ≥ 3

        Exclusion Criteria:

          1. Allergic to diacerein

          2. Use Cyclosporin within 30 days

          3. Eyelid problem

          4. Change artificial tear while in the study

          5. Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ngamjit Kasetsuwan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, Chulalongkorn University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ngamjit Kasetsuwan</last_name>
    <phone>+66819200553</phone>
    <email>ngamjitk@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathapon Treewipanon</last_name>
    <phone>+66896932677</phone>
    <email>book156@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of medicine, Chulalongkorn university</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ngamjit Kasetsuwan, MD</last_name>
      <phone>662-256-4142</phone>
      <email>ngamjitk@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nathapon Treewipanon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Usanee Reinprayoon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vannarut Satitpitakul, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thanathep Tanpowpong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Ngamjit Kasetsuwan</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Dry Eye Syndromes</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Ocular surface inflammation</keyword>
  <keyword>Interleukin-1</keyword>
  <keyword>Interleukin-1 receptor antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diacetylrhein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

